High-dose cyclophosphamide without stem-cell rescue for refractory CIDP.
Four patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who were refractory to conventional treatment were treated with high-dose cyclophosphamide (200 mg/kg over 4 days). All improved in functional status and muscle strength. Nerve conduction studies improved in three of four. Other immunomodulatory medications have been discontinued. High-dose cyclophosphamide can be given safely to patients with CIDP and patients with disease persistence after standard therapy may have a response that lasts for over 3 years and results in long-term disease remission.
Brannagan
T H
TH
Department of Neurology, MCP-Hahnemann University, Philadelphia, PA, USA. THB2006@med.cornell.edu
Pradhan
A
A
Heiman-Patterson
T
T
Winkelman
A C
AC
Styler
M J
MJ
Topolsky
D L
DL
Crilley
P A
PA
Schwartzman
R J
RJ
Brodsky
I
I
Gladstone
D E
DE
D000328:Adult; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000276:immunology; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide